AR067439A1 - Virus quimericos antigenicos de virus de encefalitis de st. louis/virus dengue tipo 4 - Google Patents

Virus quimericos antigenicos de virus de encefalitis de st. louis/virus dengue tipo 4

Info

Publication number
AR067439A1
AR067439A1 ARP080102567A ARP080102567A AR067439A1 AR 067439 A1 AR067439 A1 AR 067439A1 AR P080102567 A ARP080102567 A AR P080102567A AR P080102567 A ARP080102567 A AR P080102567A AR 067439 A1 AR067439 A1 AR 067439A1
Authority
AR
Argentina
Prior art keywords
louis
viruses
virus
dengue type
virus dengue
Prior art date
Application number
ARP080102567A
Other languages
English (en)
Inventor
Alexander G Pietnev
Jr Joseph E Blaney
Stephen Whitehead
Brian Murphy
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Publication of AR067439A1 publication Critical patent/AR067439A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Virus quiméricos antigénicos atenuados de virus de encefalitis de St. Louis/virus dengue tipo 4, los cuales se pueden usar para preparar composiciones inmunogénicas, vacunas y reactivos de diagnostico. Se proveen métodos para preparar y usar los anteriores. Reivindicacion 1: Un ácido nucleico que comprende una primera secuencia de nucleotidos que codifica al menos una proteína estructural de un virus SLE y una segunda secuencia de nucleotidos que codifica al menos una proteína no estructural de un virus dengue.
ARP080102567A 2007-06-14 2008-06-17 Virus quimericos antigenicos de virus de encefalitis de st. louis/virus dengue tipo 4 AR067439A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93473007P 2007-06-14 2007-06-14

Publications (1)

Publication Number Publication Date
AR067439A1 true AR067439A1 (es) 2009-10-14

Family

ID=39744908

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102567A AR067439A1 (es) 2007-06-14 2008-06-17 Virus quimericos antigenicos de virus de encefalitis de st. louis/virus dengue tipo 4

Country Status (3)

Country Link
US (1) US20100316670A1 (es)
AR (1) AR067439A1 (es)
WO (1) WO2008157136A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2435572B1 (en) 2009-05-28 2017-08-16 The United States of America, as Represented by The Secretary, Department of Health and Human Services Antigenic chimeric tick-borne encephalitis virus (tbev)/dengue virus type 4 (den4) recombinant viruses
SG176299A1 (en) 2009-06-01 2012-01-30 Inviragen Inc Compositions and methods for administration of vaccines against dengue virus
CA2770888C (en) 2009-08-31 2020-04-14 Gen-Probe Incorporated Dengue virus assay
TW201428101A (zh) * 2012-11-08 2014-07-16 Inviragen Inc 登革熱病毒血清型４型之建構物的組成物、方法及用途
CA2933472A1 (en) 2012-12-14 2014-06-19 Takeda Vaccines, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
JP2019511221A (ja) 2016-03-11 2019-04-25 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 弱毒化された生ジカウイルスワクチン
WO2018129160A1 (en) 2017-01-06 2018-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Live attenuated flavivirus vaccines and methods of using and making same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
EP2290109B1 (en) * 2001-05-22 2014-08-13 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
EP2339011B1 (en) * 2002-01-10 2015-04-15 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES West Nile virus and Dengue 4 virus chimeras for use in a live virus vaccine to prevent disease caused by west nile virus

Also Published As

Publication number Publication date
WO2008157136A1 (en) 2008-12-24
US20100316670A1 (en) 2010-12-16

Similar Documents

Publication Publication Date Title
AR067439A1 (es) Virus quimericos antigenicos de virus de encefalitis de st. louis/virus dengue tipo 4
ECSP088599A (es) Virus quiméricos que presentan proteínas de superficie no nativas y usos de los mismos
AR071220A1 (es) Astrovirus aviario depositado bajo el nuero cncm i-3895
EA201201025A1 (ru) Молекулы нуклеиновых кислот гриппа и вакцины, изготовленные из них
EA201591888A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
BRPI0908489A2 (pt) uso de compostos químicos e método para desenhar compostos químicos que atenuam ou inibem a infecção pelo vírus da dengue
BRPI0913012A2 (pt) vírus do nilo ocidental/da dengue quiméricos
BR112014010823A2 (pt) anticorpos gp41 neutralizantes e seus usos
WO2008039267A3 (en) Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
ECSP088591A (es) Anticuerpos anti-il-23 humanos, composiciones, metodos y usos
MX2013010620A (es) Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo.
JP2015524421A5 (es)
ES2421543T3 (es) Método para la preparación de virus y proteínas del PRRS, y kits de pruebas de diagnóstico para su detección
CL2011001343A1 (es) Pestivirus quimerico que comprende un virus de la diarrea viral bovina (bvdv) que expresa proteina erns de antilope; celula huesped que lo comprende; acido nucleico que lo codifica; composicion inmunogenica que comprende el pestivirus; vacuna marcadora que comprende el bvdv quimerico.
EA201001045A1 (ru) Модифицированный вирус гриппа
WO2012065105A3 (en) Chimeric flavivirus vaccines
AR047581A1 (es) Vacunas de calicivirus felino
AR059005A1 (es) Virus quimericos del dengue
CO6541529A2 (es) Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quimericos
AR057225A1 (es) Vacunas marcadas contra el virus de la diarrea virica bovina
CO6670515A2 (es) Vectores de parapoxvirus
AR082281A1 (es) Vectores de parapoxvirus
GB2429711A (en) Heart and skeletal muscle inflammation (HSMI) virus
BRPI0914060A2 (pt) formulação para o tratamento de células que expressem proteínas do hcv e de mamíferos portadores de hepatite c, método para o tratamento de células infectadas pela cepa pj6/jfh1 do hcv genótipo 2a e uso de uma formulação
AR085800A1 (es) Vacuna de rinitis equina

Legal Events

Date Code Title Description
FB Suspension of granting procedure